Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merus
Merus
Top ten biopharma R&D deals of 2024
Nature
Wed, 06/5/24 - 11:24 am
R&D
Novartis
Argo Biopharmaceutical
Roche
MOMA Therapeutics
Boehringer Ingelheim
Suzhou Ribo Life Science
Eli Lilly
Isomorphic Labs
Merus
Gilead Sciences
Novo Nordisk
Neomorph
AbbVie
Umoja Biopharma
Merck KGaA
Caris Life Sciences
Voyager Therapeutics
ASCO24 preview: A look at some of the cancer meeting’s hottest abstracts
BioSpace
Fri, 05/31/24 - 11:03 am
ASCO 2024
Merus
JNJ
CAR-T
Legend Biotech
Pfizer
Genmab
Nanobiotix
Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab
Fierce Biotech
Wed, 03/6/24 - 11:30 am
Gilead Sciences
Merus
T-cell engager
ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?
Fierce Biotech
Tue, 06/7/22 - 10:16 am
ASCO 2022
Merus
zenocutuzumab
NRG1 fusion-positive cancer
#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC
Endpoints
Sat, 06/5/21 - 02:17 pm
ASCO 2021
Merus
Eli Lilly
clinical trials
solid tumors
Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies
Endpoints
Tue, 01/19/21 - 10:39 am
Eli Lilly
oncology
Merus
drug discovery
Merus charts early promise for cancer drug targeting NRG1 fusions
Fierce Biotech
Mon, 10/28/19 - 10:40 am
Merus
bispecific antibodies
zenocutuzumab
NRG1 fusion
4 Stocks Battling Breast Cancer
Motley Fool
Sat, 10/26/19 - 02:18 pm
Seattle Genetics
Macrogenics
Merus
Zymeworks
Top Presentations to Look for at ASCO
Yahoo/24-7 Wall St
Tue, 05/30/17 - 11:35 am
ASCO 2017
Merck
AbbVie
Eli Lilly
Bluebird Bio
Epizyme
Juno Therapeutics
Kite
Merus
Incyte puts up $200M in bispecifics deal with Merus
BioPharma Dive
Thu, 12/22/16 - 10:21 am
Incyte
Merus
bispecific antibodies
Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO
Fierce Biotech
Thu, 04/9/15 - 10:01 am
IPOs
Merus
JNJ
Novartis
Pfizer
immuno-oncology
J&J makes an R&D splash with $42M venture play, biotech collaborations
Fierce Biotech
Thu, 10/3/13 - 05:35 pm
R&D
JNJ
Effimune
Merus
Novartis Venture Fund
Pfizer Venture Investments